Utility of serological markers in inflammatory bowel diseases: Gadget or magic?

M. Papp, I. Altorjay, Gary L. Norman, P. Lakatos

Research output: Article

91 Citations (Scopus)

Abstract

The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly expanding. Although anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely investigated, an increasing amount of experimental data is available on newly discovered antibodies directed against various microbial antigens. The role of the assessment of various antibodies in the current IBD diagnostic algorithm is often questionable due to their limited sensitivity. In contrast, the association of serologic markers with disease behavior and phenotype is becoming increasingly well-established. An increasing number of observations confirms that patients with Crohn's disease expressing multiple serologic markers at high titers are more likely to have complicated small bowel disease (e.g. stricture and/or perforation) and are at higher risk for surgery than those without, or with low titers of antibodies. Creating homogenous disease sub-groups based on serologic response may help develop more standardized therapeutic approaches and may help in a better understanding of the pathomechanism of IBD. Further prospective clinical studies are needed to establish the clinical role of serologic tests in IBD.

Original languageEnglish
Pages (from-to)2028-2036
Number of pages9
JournalWorld Journal of Gastroenterology
Volume13
Issue number14
Publication statusPublished - ápr. 14 2007

Fingerprint

Magic
Inflammatory Bowel Diseases
Antibodies
Antineutrophil Cytoplasmic Antibodies
Serologic Tests
Crohn Disease
Saccharomyces cerevisiae
Pathologic Constriction
Prospective Studies
Phenotype
Antigens
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{9bb7cf608bdb4045a4cd33525b281dc9,
title = "Utility of serological markers in inflammatory bowel diseases: Gadget or magic?",
abstract = "The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly expanding. Although anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely investigated, an increasing amount of experimental data is available on newly discovered antibodies directed against various microbial antigens. The role of the assessment of various antibodies in the current IBD diagnostic algorithm is often questionable due to their limited sensitivity. In contrast, the association of serologic markers with disease behavior and phenotype is becoming increasingly well-established. An increasing number of observations confirms that patients with Crohn's disease expressing multiple serologic markers at high titers are more likely to have complicated small bowel disease (e.g. stricture and/or perforation) and are at higher risk for surgery than those without, or with low titers of antibodies. Creating homogenous disease sub-groups based on serologic response may help develop more standardized therapeutic approaches and may help in a better understanding of the pathomechanism of IBD. Further prospective clinical studies are needed to establish the clinical role of serologic tests in IBD.",
keywords = "Anti-Saccharomyces cerevisiae mannan antibodies, Antineutrophil cytoplasmic antibodies, Crohn's disease, Indeterminate colitis, Inflammatory bowel disease, Outer membrane porin, Serologic markers, Ulcerative colitis",
author = "M. Papp and I. Altorjay and Norman, {Gary L.} and P. Lakatos",
year = "2007",
month = "4",
day = "14",
language = "English",
volume = "13",
pages = "2028--2036",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "14",

}

TY - JOUR

T1 - Utility of serological markers in inflammatory bowel diseases

T2 - Gadget or magic?

AU - Papp, M.

AU - Altorjay, I.

AU - Norman, Gary L.

AU - Lakatos, P.

PY - 2007/4/14

Y1 - 2007/4/14

N2 - The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly expanding. Although anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely investigated, an increasing amount of experimental data is available on newly discovered antibodies directed against various microbial antigens. The role of the assessment of various antibodies in the current IBD diagnostic algorithm is often questionable due to their limited sensitivity. In contrast, the association of serologic markers with disease behavior and phenotype is becoming increasingly well-established. An increasing number of observations confirms that patients with Crohn's disease expressing multiple serologic markers at high titers are more likely to have complicated small bowel disease (e.g. stricture and/or perforation) and are at higher risk for surgery than those without, or with low titers of antibodies. Creating homogenous disease sub-groups based on serologic response may help develop more standardized therapeutic approaches and may help in a better understanding of the pathomechanism of IBD. Further prospective clinical studies are needed to establish the clinical role of serologic tests in IBD.

AB - The panel of serologic markers for inflammatory bowel diseases (IBD) is rapidly expanding. Although anti-Saccharomyces cerevisiae antibodies (ASCA) and atypical perinuclear antineutrophil cytoplasmic antibodies (P-ANCA) remain the most widely investigated, an increasing amount of experimental data is available on newly discovered antibodies directed against various microbial antigens. The role of the assessment of various antibodies in the current IBD diagnostic algorithm is often questionable due to their limited sensitivity. In contrast, the association of serologic markers with disease behavior and phenotype is becoming increasingly well-established. An increasing number of observations confirms that patients with Crohn's disease expressing multiple serologic markers at high titers are more likely to have complicated small bowel disease (e.g. stricture and/or perforation) and are at higher risk for surgery than those without, or with low titers of antibodies. Creating homogenous disease sub-groups based on serologic response may help develop more standardized therapeutic approaches and may help in a better understanding of the pathomechanism of IBD. Further prospective clinical studies are needed to establish the clinical role of serologic tests in IBD.

KW - Anti-Saccharomyces cerevisiae mannan antibodies

KW - Antineutrophil cytoplasmic antibodies

KW - Crohn's disease

KW - Indeterminate colitis

KW - Inflammatory bowel disease

KW - Outer membrane porin

KW - Serologic markers

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=34249047618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249047618&partnerID=8YFLogxK

M3 - Article

C2 - 17465443

AN - SCOPUS:34249047618

VL - 13

SP - 2028

EP - 2036

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 14

ER -